Posluma Generic Name & Formulations
Multi-dose vial (25mL)—1
Mechanism of Action
Flotufolastat F 18 binds to PSMA expressed on cells, including prostate cancer cells, and is internalized. Prostate cancer cells usually overexpress PSMA. Fluorine-18 is a ß+ emitting radionuclide that can be detected using positron emission tomography.
For positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or with suspected recurrence based on elevated serum PSA level.
Posluma Dosage and Administration
Give as IV bolus inj. 296MBq (8mCi); max volume 5mL (undiluted). Follow with NaCl 0.9% IV flush. Acquire images ~60mins after inj. The radiation absorbed dose from 296MBq (8mCi) dose is 4.1mSv.
Posluma Boxed Warnings
Risk of radiation exposure. Should only be used by trained and experienced physicians in the safe use and handling of radioactive materials to minimize radiation exposure. Risk for image misinterpretation and other errors; clinical correlation recommended. Contributes to patient's overall long-term cumulative radiation exposure. Advise to hydrate prior to and post-inj; void frequently after. Pregnancy, nursing mothers: not indicated for females.
Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway may affect flotufolastat F 18 uptake.
Posluma Adverse Reactions
Diarrhea, BP increase, inj site pain.
Posluma Clinical Trials
Posluma Patient Counseling